Results for announcement to the market

 

The attached Form 10-Q Quarterly Report for the quarter ended September 30, 2026 (the “Form 10-Q”) has been filed with the U.S. Securities and Exchange Commission (“SEC”).  It includes the condensed consolidated financial statements which have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are denominated in U.S. dollars.

 

The following supplementary information is provided in connection with the Form 10-Q to satisfy the Company's ongoing disclosure obligations under the ASX Listing Rules. The information has been prepared in accordance with the waiver conditions granted by the ASX in relation to 4.7C for quarterly activity reports, and should be read in conjunction with the Form 10-Q.

 

Details of business activities during the quarter

 

Refer to the Form 10-Q and the “Anteris Announces Results for the Third Quarter of 2026” announcement lodged with the ASX on November 11, 2026.

 

Aggregate amount of payments to related parties and their associates

 

During the third quarter of 2026, the aggregate amount of payments to related parties and their associates was US$576 thousand.  The quarterly amount includes fees paid to non-executive directors, as well as salary payments to the CEO, President and CFO.  These payments were included in cash flows from operating activities.

 

There were no payments to related parties or their associates included in cash flows from investing activities.

 

ENDS

 

 

About Anteris

 

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

 

Anteris’ lead product, the DurAVR^® THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR^® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.  DurAVR^® THV is made using a single piece of molded ADAPT^® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT^® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR^® THV System is comprised of the DurAVR^® valve, the ADAPT^® tissue, and the balloon-expandable ComASUR^® Delivery System.

 

Forward-Looking Statements

 

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 and the Form 10-Q, each filed with the SEC and ASX. Actual future events may vary from these forward-looking statements and readers are cautioned not to put undue reliance on forward-looking statements. Other than as required by law, Anteris gives no representation or guarantee that the occurrence of any of the events or circumstances expressed or implied in these statements will occur. In addition, except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

 

Authorisation and Additional information

 

This announcement was authorised for release on the ASX by the Board of Directors.

 

For more information:

 

2